Compare General Dynamics Corporation (GD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Viatris Inc — how do they compare? General Dynamics Corporation trades at $367.2 (market cap $98.88B), while Viatris Inc trades at $17.26 (market cap $19.44B). The key difference: General Dynamics Corporation is far larger — about 5.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| GD | VTRS | |
|---|---|---|
Market Cap | $98.88B | $19.44B |
Sector | Industrials | Health |
52-Week High | $376.88 | $17.39 |
52-Week Low | $297.05 | $8.74 |
Enterprise Value | $105.06B | $31.65B |
Dividend Yield | 1.74% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $366.40, down 0.84% on the day, with strong technical momentum indicated by bullish moving averages and oscillators. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $4.10 versus $3.67, continuing a trend of earnings outperformance. Revenue growth has been consistent, reaching $52.55 billion in 2025 with an 8.07% net income margin. Analyst sentiment remains positive with a $395.83 consensus price target and 53% buy ratings.
The outlook for GD is favorable given strong defense spending tailwinds and a growing $130.8 billion backlog, particularly in marine systems. However, risks include execution challenges on large contracts and potential defense budget volatility. The stock's current valuation at 23x P/E appears reasonable relative to earnings growth prospects, positioning it as a core defense holding for long-term investors.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
